Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
US11975063B2 · kind B2 · utility
0Cited by
7References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 1, 2022 |
| Grant date | May 7, 2024 |
| Priority date | — |
| Expiry date | Mar 20, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18643
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing Respiratory Syncytial Virus (RSV) G protein or a recombinant RSV G protein, as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the RSV G protein or the recombinant RSV G protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to RSV and HPIV3 in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.